Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
Follow Pharmacy_Times:
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Related Articles
Though the fall semester is underway, it’s not too late to change your studying habits.
Author, speaker, and entrepreneur Guy Kawasaki inspired independent community pharmacists to be enchanting.
Although pharmacies can legally dispense remaining refills of prescriptions for rescheduled hydrocodone combination products submitted prior to October 6, 2014, over the next 6 months, many drug chains have chosen not to honor those refills.
Latest Issues
$auto_registration$